A placebo-controlled, crossover trial to investigate the efficacy of tiotropium bromide or placebo added to usual care in stable symptomatic post-hematopoietic stem cell transplantation (HSCT) bronchiolitis obliterans syndrome (BOS)
This study was approved by the Research Ethics Committees of Imam Khomeini Hospital Complex, Tehran University of Medical Science. Recruitment started in September 2022, with 20 patients randomized. The treatment follow-up of participants with tiotropium is currently ongoing and is due to finish in April 2024. The authors will disseminate the findings in peer-reviewed publications, conferences, and seminar presentations.Trial registrationIranian Registry of Clinical Trial (IRCT) IRCT20200415047080N3. Registered on 2022 –07-12, 1401/04/21. (Source: Trials)
Source: Trials - April 6, 2024 Category: Research Source Type: clinical trials
A Trial to Assess the Bioequivalence of Generic Tiotropium Bromide Inhalation Powder and Reference Product in Healthy Adult Participants Under Fasting Conditions (Pilot)
Conditions: Chronic Obstructive Pulmonary Disease Interventions: Drug: Tiotropium Bromide Inhalation Powder; Drug: Spiriva HandiHaler Sponsors: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 22, 2024 Category: Research Source Type: clinical trials
ANTES B+ Clinical Trial
Conditions: Chronic Obstructive Pulmonary Disease Interventions: Drug: Trelegy Ellipta 100/62.5/25Mcg Inh 30D; Drug: Brimica; Drug: Duaklir; Drug: Ultibro; Drug: Ulunar; Drug: Xoterna; Drug: Anoro; Drug: Laventair; Drug: Spiolto Respimat; Drug: Yanimo; Drug: Foradil; Drug: Broncoral; Drug: Formoterol stada; Drug: Oxis; Drug: Formatris; Drug: Formoterol Aldo; Drug: Onbrez; Drug: Oslif; Drug: Hirobriz; Drug: Striverdi; Drug: Beglan; Drug: Betamican; Drug: Inaspir; Drug: Serevent; Drug: Soltel; Drug: Eklira; Drug: Bretaris; Drug: Seebri; Drug: Tovanor; Drug: Enurev; Drug: Spiriva; Drug: Tavulus; Drug: Sirkava; Drug: Braltus; ...
Source: ClinicalTrials.gov - February 28, 2024 Category: Research Source Type: clinical trials
Open Label Study to Assess the Effect of Patient Use and Robustness of Tiotropium 18ug Inhalation Powder, Hard Capsule,Zephir Inhaler Device
Conditions: COPD Interventions: Drug: Tiotropium 18 µg inhalation powder, hard capsule; Device: Zephir inhaler Sponsors: Xiromed LLC; Laboratorios Liconsa Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 12, 2024 Category: Research Source Type: clinical trials
QualiTy of Life Evaluation in Patients With ChRonic ObstructIve Pulmonary Disease Who Require Tiotropium as additiOnal treatmeNt.
Conditions: COPD Interventions: Other: Tiotropium treated patients Sponsors: Elpen Pharmaceutical Co. Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 14, 2023 Category: Research Source Type: clinical trials
Morbid Rates After Spiriva Chronic Obstructive Pulmonary Disease (COPD) Protocol Change
Condition: Pulmonary Disease, Chronic Obstructive Intervention: Sponsor: Boehringer Ingelheim Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 25, 2023 Category: Research Source Type: clinical trials
Morbid Rates After Spiriva Chronic Obstructive Pulmonary Disease (COPD) Protocol Change
Conditions: Pulmonary Disease, Chronic Obstructive Sponsors: Boehringer Ingelheim Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 25, 2023 Category: Research Source Type: clinical trials
Bioequivalence Study of Tiotropium 18 μg Inhalation Powder, Hard Capsule With Spiriva®Handihaler® 18 μg Inhalation Powder, Hard Capsule in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Condition: COPD Interventions: Combination Product: Test Product - Tiotropium Bromide Inhalation Powder 18 mcg; Combination Product: Spiriva Handihaler (Tiotropium Bromide) 18 mcg; Combination Product: Placebo Sponsors: Xiromed LLC; Exeltis Healthcare S.L; Laboratorios Liconsa SA Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 14, 2023 Category: Research Source Type: clinical trials
